Aquestive Therapeutics Inc (NASDAQ:AQST) shares, rose in value, with the stock price up by 0.77% to the previous day’s close as strong demand from buyers drove the stock to $3.93.
Actively observing the price movement in the last trading, the stock closed the session at $3.90. Referring to stock’s 52-week performance, its high was $6.23, and the low was $1.15. On the whole, AQST has fluctuated by -3.20% over the past month.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 50.21M, with a low estimate of 10.9M and a high estimate of 13M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 12.26M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AQST’s technical picture suggests that short-term indicators denote the stock is a 25% Buy on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of AQST currently trading nearly -4.58% and -3.78% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 45.94, while the 7-day volatility ratio is showing 8.73% which for the 30-day chart, stands at 7.75%. Furthermore, Aquestive Therapeutics Inc (AQST)’s beta value is 2.91, and its average true range (ATR) is 0.36.
A comparison of Aquestive Therapeutics Inc (AQST) with its peers suggests the former has fared considerably weaker in the market. AQST showed an intraday change of 0.77% in last session, and over the past year, it grew by 207.03%%.
Data on historical trading for Aquestive Therapeutics Inc (NASDAQ:AQST) indicates that the trading volumes over the past 3 months, they’ve averaged 2.52 million. According to company’s latest data on outstanding shares, there are 89.97 million shares outstanding.
Nearly 11.31% of Aquestive Therapeutics Inc’s shares belong to company insiders and institutional investors own 26.41% of the company’s shares. The stock has risen by 94.55% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AQST stock heading into the next quarter.
